BioAtla和GATC Health宣布达成价值4000万美元的特殊目的汽车交易，初步成交金额为500万美元，预计2026年第一季度剩余金额为3500万美元，用于资助Ozuriiftamab Vedotin第三阶段注册试验2L+ OPSCC

2025-12-31 20:03

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.
BioAtla to retain 65% ownership of Oz-V across all solid tumor indications after completion of the SPV transaction.
BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval and enrollment anticipated to begin early 2026.
Oz-V targets ROR2, an important receptor that not only drives tumor progression, but also regulates cellular senescence, which is linked to chronic diseases associated with aging.